VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS

被引：0
|
作者：
Nelson, David R. [1 ]
Gane, Edward J. [2 ]
Jacobson, Ira M. [3 ]
Di Bisceglie, Adrian M. [4 ]
Alves, Katia [5 ]
Koziel, Margaret J. [5 ]
De Souza, Cynthia [5 ]
Kieffer, Tara L. [5 ]
George, Shelley [5 ]
Rosario, Maria [5 ]
Kauffman, Robert S. [5 ]
Sulkowski, Mark S. [6 ]
机构：
[1] Univ Florida, Coll Med, Gainesville, FL USA
[2] Auckland City Hosp, Auckland, New Zealand
[3] Weill Cornell Med Coll, New York, NY USA
[4] St Louis Univ, Sch Med, St Louis, MO USA
[5] Vertex Pharmacuet Inc, Cambridge, MA USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1435A / 1435A
页数：1
相关论文
共 50 条
  • [41] Resistance Analysis of Treatment-Naive HCV Genotype 1-6 Infected Patients Treated with Sofosbuvir in Combination with GS-5816 for 12 Weeks
    Doehle, Brian
    Gontcharova, Viktoria
    Chodavarapu, Ramakrishna K.
    McNally, John
    Chung, Raymond T.
    Everson, Gregory T.
    McHutchison, John G.
    Miller, Michael D.
    Mo, Hongmei
    HEPATOLOGY, 2014, 60 : 1138A - 1139A
  • [42] TMC435 IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1 PATIENTS: FINAL ANALYSIS OF THE PILLAR PHASE IIB STUDY
    Fried, Michael
    Buti, Maria
    Dore, Gregory J.
    Flisiak, Robert
    Ferenci, Peter
    Jacobson, Ira M.
    Marcellin, Patrick
    Manns, Michael P.
    Nikitin, Igor
    Poordad, F. Fred
    Sherman, Morris
    Zeuzem, Stefan
    Lenz, Oliver
    Peeters, Monika
    Sekar, Vanitha
    De Smedt, Goedele
    HEPATOLOGY, 2011, 54 : 1429A - 1429A
  • [43] Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Safety/Efficacy of the REFRESH Study
    Brown, R.
    Russo, M.
    Levitsky, J.
    Brown, K.
    Fontana, R.
    Vargas, H.
    Yoshida, E.
    Bsharat, M.
    Rubin, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 145 - 145
  • [44] Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Pharmacokinetics of the REFRESH Study.
    Vargas, H.
    Dai, Y.
    Brown, K.
    Russo, M.
    Yoshida, E.
    Fontana, R.
    Levitsky, J.
    Rubin, R.
    Garg, V.
    Brown, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 347 - 347
  • [45] TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA 2B AND RIBAVIRIN THERAPY FOR GENOTYPE 1 CHRONIC HCV PATIENTS: PHASE 3 STUDY IN JAPAN
    Okanoue, Takeshi
    Hayashi, Norio
    Tsubouchi, Hirohito
    Chayama, Kazuaki
    Toyota, Joji
    Kumada, Hiromitsu
    HEPATOLOGY, 2011, 54 : 985A - 986A
  • [46] Evaluation of viral variants during a Phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype I-infected patients
    Kieffer, Tara
    Zhou, Yi
    Zhang, Eileen
    Marcial, Michelle
    Byrn, Randal
    Pfeiffer, Thomas
    Miller, Janice
    Tigges, Ann
    Bartels, Doug
    Kwong, Ann
    Ferenci, Peter
    Dusheiko, Geoffrey
    Zeuzem, Stefan
    Pawlotsky, Jean-Michel
    HEPATOLOGY, 2007, 46 (04) : 862A - 862A
  • [47] SILEN-C3: TREATMENT FOR 12 OR 24 WEEKS WITH BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAiVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION
    Dieterich, Douglas
    Asselah, Tarik
    Guyader, Dominique
    Berg, Thomas
    Ceausu, Emanoil
    Preotescu, Liliana
    Schuchmann, Marcus
    Mauss, Stefan
    Ratziu, Vlad
    Ferenci, Peter
    Larrey, Dominique G.
    Maieron, Andreas
    Biermer, Michael
    Stern, Jerry O.
    Scherer, Joe
    Kubiak, Rene
    Boecher, Wulf O.
    HEPATOLOGY, 2011, 54 : 378A - 378A
  • [48] TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY
    Lenz, Oliver
    Fevery, Bart
    Vijgen, Leen
    Verbeeck, Jannick
    Peeters, Monika
    Beumont, Maria
    Fried, Michael W.
    Picchio, Gaston
    HEPATOLOGY, 2011, 54 : 985A - 985A
  • [49] PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR -ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1. HEPATITIS C: WEEK 4 INTERIM RESULTS (vol 48, pg 4, 2008)
    Forns, X.
    Marcellin, P.
    Goeser, T.
    Ferenci, P.
    Nevens, F.
    Carosi, G.
    Drenth, J. P.
    De Backer, K.
    van Heeswijk, R.
    Vangeneugden, T. J.
    Picchio, G.
    Beumont-Mauviel, M.
    HEPATOLOGY, 2008, 48 (06) : 2093 - 2093
  • [50] A PHASE 2B STUDY OF TELAPREVIR WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 NULL AND PARTIAL RESPONDERS AND RELAPSERS FOLLOWING A PRIOR COURSE OF PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: PROVE3 INTERIM RESULTS
    McHutchison, John G.
    Shiffman, Mitchell L.
    Terrault, Norah
    Manns, Michael P.
    Di Bisceglie, Adrian M.
    Jacobson, Ira M.
    Afdhal, Nezom H.
    Heathcote, E. Jenny
    Zeuzem, Stefan
    Reesink, Hendrik W.
    George, Shelley
    Adda, Nathalie
    Muir, Andrew J.
    HEPATOLOGY, 2008, 48 (04) : 431A - 432A
12345